BACKGROUND: Q fever is a zoonosis caused by Coxiella burnetii. After a large outbreak occurred in the Chamonix Valley in the French Alps in 2002, an extensive surveillance was conducted, to describe the variations in the clinical expression of acute Q fever according to host factors, as well as to monitor the risk of evolution of acute Q fever to chronic Q fever in patients at risk. METHODS: Three groups of patients with risk factors for evolution of acute Q fever to chronic Q fever were considered: 376 pregnant women, 19 immunocompromised patients, and 91 patients with valvular or vascular abnormalities. A group of 578 people without risk factors for evolution of acute Q fever to chronic Q fever was also tested. Diagnosis of Q fever was based on serologic testing by immunofluorescence assay. RESULTS: Between 30 August 2002 and 31 July 2003, a total of 1946 serum samples obtained from 1064 persons were tested. A total of 101 patients (9.3%) had acute Q fever diagnosed, and 5 patients (0.5%) had chronic Q fever diagnosed. A diagnosis of acute Q fever was established for 11 pregnant women (2.6% of 379 pregnancies), 5 patients with valvular disease (5.5%), and 85 people without risk factors (14.7%) (71 [27.9%] of 254 symptomatic patients and 14 [4.3%] of 324 asymptomatic patients). A new pregnancy in a woman with negative results of serologic tests for Q fever exposes the woman to a new risk for acute Q fever able to evolve to chronic Q fever. The rates of clinical expression were 90.6% in adult men, 75% in adult women, and 33.3% in children, and they were significantly lower (9.1%) in pregnant women. Evolution to chronic Q fever was observed in 5 patients. CONCLUSION: This study emphasizes the importance of active surveillance in postepidemic conditions, especially among patients at risk, as well as the importance of systematic serologic testing during pregnancy.
BACKGROUND:Q fever is a zoonosis caused by Coxiella burnetii. After a large outbreak occurred in the Chamonix Valley in the French Alps in 2002, an extensive surveillance was conducted, to describe the variations in the clinical expression of acute Q fever according to host factors, as well as to monitor the risk of evolution of acute Q fever to chronic Q fever in patients at risk. METHODS: Three groups of patients with risk factors for evolution of acute Q fever to chronic Q fever were considered: 376 pregnant women, 19 immunocompromised patients, and 91 patients with valvular or vascular abnormalities. A group of 578 people without risk factors for evolution of acute Q fever to chronic Q fever was also tested. Diagnosis of Q fever was based on serologic testing by immunofluorescence assay. RESULTS: Between 30 August 2002 and 31 July 2003, a total of 1946 serum samples obtained from 1064 persons were tested. A total of 101 patients (9.3%) had acute Q fever diagnosed, and 5 patients (0.5%) had chronic Q fever diagnosed. A diagnosis of acute Q fever was established for 11 pregnant women (2.6% of 379 pregnancies), 5 patients with valvular disease (5.5%), and 85 people without risk factors (14.7%) (71 [27.9%] of 254 symptomatic patients and 14 [4.3%] of 324 asymptomatic patients). A new pregnancy in a woman with negative results of serologic tests for Q fever exposes the woman to a new risk for acute Q fever able to evolve to chronic Q fever. The rates of clinical expression were 90.6% in adult men, 75% in adult women, and 33.3% in children, and they were significantly lower (9.1%) in pregnant women. Evolution to chronic Q fever was observed in 5 patients. CONCLUSION: This study emphasizes the importance of active surveillance in postepidemic conditions, especially among patients at risk, as well as the importance of systematic serologic testing during pregnancy.
Authors: Linda M Kampschreur; Jan Jelrik Oosterheert; Annemarie M C Koop; Marjolijn C A Wegdam-Blans; Corine E Delsing; Chantal P Bleeker-Rovers; Monique G L De Jager-Leclercq; Cornelis A R Groot; Tom Sprong; Marrigje H Nabuurs-Franssen; Nicole H M Renders; Marjo E van Kasteren; Yvonne Soethoudt; Sybrandus N Blank; Marjolijn J H Pronk; Rolf H H Groenwold; Andy I M Hoepelman; Peter C Wever Journal: Clin Vaccine Immunol Date: 2012-03-21
Authors: J C J P Hagenaars; N H M Renders; A S van Petersen; S O A Shamelian; M G L de Jager-Leclercq; F L Moll; P C Wever; O H J Koning Journal: Eur J Clin Microbiol Infect Dis Date: 2014-03-12 Impact factor: 3.267
Authors: Janna M Munster; Alexander C A P Leenders; Wim van der Hoek; Peter M Schneeberger; Ariene Rietveld; Josien Riphagen-Dalhuisen; Ronald P Stolk; Carl J C M Hamilton; Esther de Vries; Jamie Meekelenkamp; Jerome R Lo-Ten-Foe; Albertus Timmer; Lolkje T W De Jong-van den Berg; Jan G Aarnoudse; Eelko Hak Journal: BMC Womens Health Date: 2010-11-01 Impact factor: 2.809
Authors: Linda M Kampschreur; Corine E Delsing; Rolf H H Groenwold; Marjolijn C A Wegdam-Blans; Chantal P Bleeker-Rovers; Monique G L de Jager-Leclercq; Andy I M Hoepelman; Marjo E van Kasteren; Jacqueline Buijs; Nicole H M Renders; Marrigje H Nabuurs-Franssen; Jan Jelrik Oosterheert; Peter C Wever Journal: J Clin Microbiol Date: 2014-03-05 Impact factor: 5.948
Authors: Marit M A de Lange; Laura E V Gijsen; Cornelia C H Wielders; Wim van der Hoek; Arko Scheepmaker; Peter M Schneeberger Journal: Clin Infect Dis Date: 2018-07-18 Impact factor: 9.079
Authors: Regan N Theiler; Sonja A Rasmussen; Tracee A Treadwell; Denise J Jamieson Journal: Infect Dis Clin North Am Date: 2008-12 Impact factor: 5.982